Identification of novel signaling components in genistein-regulated signaling pathways by quantitative phosphoproteomics

Journal of Proteomics

Volumn 75, Issue 2, 2011, Pages 695-707

  Yan, Guang Rong ^a   Yin, Xing Feng ^a   Xiao, Chuan Le ^a   Tan, Zi Lu ^a   Xu, Song Hui ^a   He, Qing Yu ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Genistein; Phosphoproteome; Phosphorylation; Proteomics; Signaling pathway; SILAC

Indexed keywords

DNA TOPOISOMERASE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN BAD;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; GENISTEIN; HUMANS; ISOTOPE LABELING; PHOSPHOPEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION;

GLYCINE MAX;

EID: 82355192261     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.09.008     Document Type: Article

References (56)

1. Cans C., Mangano R., Barila D., Neubauer G., Superti-Furga G. Nuclear tyrosine phosphorylation: the beginning of a map. Biochem Pharmacol 2000, 60:1203-1215.
2. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 2009, 10:356-360.
3. Sebolt-Leopold J.S., English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441:457-462.
4. Arslan M.A., Kutuk O., Basaga H. Protein kinases as drug targets in cancer. Curr Cancer Drug Targets 2006, 6:623-634.
5. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
6. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
7. Cohen P. The role of protein phosphorylation in human health and disease-delivered on June 30th 2001 at the FEBS Meeting in Lisbon. Eur J Biochem 2001, 268:5001-5010.
8. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
9. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
10. Jamadar-Shroff V., Papich M.G., Suter S.E. Soy-derived isoflavones inhibit the growth of canine lymphoid cell lines. Clin Cancer Res 2009, 15:1269-1276.
11. El Touny L.H., Banerjee P.P. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009, 69:3695-3703.
12. Yan G.R., Xiao C.L., He G.W., Yin X.F., Chen N.P., Cao Y., et al. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 2010, 10:976-986.
13. Gercel-Taylor C., Feitelson A.K., Taylor D.D. Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. Anticancer Res 2004, 24:795-800.
14. Hwang J.T., Ha J., Park O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005, 332:433-440.
15. Swami S., Krishnan A.V., Peehl D.M., Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D-3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005, 241:49-61.
16. Peterson G., Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ 1996, 7:1345-1351.
17. Banerjee S., Li Y.W., Wang Z.W., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008, 269:226-242.
18. Banerjee S., Zhang Y.X., Ali S., Bhuiyan M., Wang Z.W., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005, 65:9064-9072.
19. Kang N.J., Lee K.W., Rogozin E.A., Cho Y.Y., Heo Y.S., Bode A.M., et al. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 2007, 282:32856-32866.
20. Li Z., Li J., Mo B., Hu C., Liu H., Qi H., et al. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 2008, 24:401-409.
21. Li Z., Li J., Mo B., Hu C., Liu H., Qi H., et al. Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 2008, 22:1749-1753.
22. Gong L., Li Y., Nedeljkovic-Kurepa A., Sarkar F.H. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003, 22:4702-4709.
23. Gwin J., Drews N., Ali S., Stamschror J., Sorenson M., Rajah T.T. Effect of genistein on p90RSK phosphorylation and cell proliferation in T47D breast cancer cells. Anticancer Res 2011, 31:209-214.
24. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein-kinases. J Biol Chem 1987, 262:5592-5595.
25. Gadgeel S.M., Ali S., Philip P.A., Wozniak A., Sarkar F.H. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009, 115:2165-2176.
26. Kim E.J., Shin H.K., Park J.H.Y. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of genistein. J Med Food 2005, 8:431-438.
27. Sakla M.S., Shenouda N.S., Ansell P.J., MacDonald R.S., Lubahn D.B. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine 2007, 32:69-78.
28. Kim S.H., Kim S.H., Kim Y.B., Jeon Y.T., Lee S.C., Song Y.S. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann N Y Acad Sci 2009, 1171:495-500.
29. Zhang D.H., Tai Y.C., Wong C.H.S., Tai L.K., Koay E.S.C., Chen C.S. Molecular response of leukemia HL-60 cells to genistein treatment, a proteomics study. Leuk Res 2007, 31:75-82.
30. Yan G.R., He Q.Y. Functional proteomics to identify critical proteins in signal transduction pathways. Amino Acids 2008, 35:267-274.
31. Dai J., Wang L.S., Wu Y.B., Sheng Q.H., Wu J.R., Shieh C.H., et al. Fully automatic separation and identification of phosphopeptides by continuous pH-gradient anion exchange online coupled with reversed-phase liquid chromatography mass spectrometry. J Proteome Res 2009, 8:133-141.
32. Pan C., Gnad F., Olsen J.V., Mann M. Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 2008, 8:4534-4546.
33. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127:635-648.
34. Wu Y.B., Dai J., Yang X.L., Li S.J., Zhao S.L., Sheng Q.H., et al. Concurrent quantification of proteome and phosphoproteome to reveal system-wide association of protein phosphorylation and gene expression. Mol Cell Proteomics 2009, 8:2809-2826.
35. Macek B., Mijakovic I., Olsen J.V., Gnad F., Kumar C., Jensen P.R., et al. The serine/threonine/tyrosine phosphoproteome of the model bacterium Bacillus subtilis. Mol Cell Proteomics 2007, 6:697-707.
36. Nichols A.M., White F.M. Manual validation of peptide sequence and sites of tyrosine phosphorylation from MS/MS spectra. Methods Mol Biol 2009, 143-160.
37. Yan G.G., Li L.L., Tao Y.G., Liu S.F., Liu Y.P., Luo W., et al. Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology. Proteomics 2006, 6:1810-1821.
38. Yan G.R., Luo W., Lu Z.X., Luo X.J., Li L.L., Liu S.F., et al. Epstein-Barr virus latent membrane protein 1 mediates phosphorylation and nuclear translocation of annexin A2 by activating PKC pathway. Cell Signal 2007, 19:341-348.
39. Hunter T., Sefton B.M. Transforming gene-product of rous-sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA Biol Sci 1980, 77:1311-1315.
40. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
41. Schmelzle K., Kane S., Gridley S., Lienhard G.E., White F.M. Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 2006, 55:2171-2179.
42. Li W., Lee J., Vikis H.G., Lee S.H., Liu G., Aurandt J., et al. Activation of FAK and Src are receptor-proximal events required for netrin signaling. Nat Neurosci 2004, 7:1213-1221.
43. Meriane M., Tcherkezian J., Webber C.A., Danek E.I., Triki I., McFarlane S., et al. Phosphorylation of DCC by Fyn mediates Netrin-1 signaling in growth cone guidance. J Cell Biol 2004, 167:687-698.
44. Ma W., Shang Y., Wei Z., Wen W., Wang W., Zhang M. Phosphorylation of DCC by ERK2 is facilitated by direct docking of the receptor P1 domain to the kinase. Structure 2010, 18:1502-1511.
45. Karreth F.A., Tuveson D.A. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 2009, 19:4-11.
46. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121.
47. Nam H.J., Kim S., Lee M.W., Lee B.S., Hara T., Saya H., et al. The ERK-RSK1 activation by growth factors at G2 phase delays cell cycle progression and reduces mitotic aberrations. Cell Signal 2008, 20:1349-1358.
48. Zhu J.D., Blenis J., Yuan J.Y. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci USA 2008, 105:6584-6589.
49. DiTullio R.A., Mochan T.A., Venere M., Bartkova J., Sehested M., Bartek J., et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002, 4:998-1002.
50. Smith T.M., Gilliland K., Clawson G.A., Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SER-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008, 128:1286-1293.
51. Linding R., Jensen L.J., Ostheimer G.J., van Vugt M., Jorgensen C., Miron I.M., et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007, 129:1415-1426.
52. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
53. Ismail I.A., Kang K.S., Lee H.A., Kim J.W., Sohn Y.K. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol 2007, 575:12-20.
54. Kyle E., Neckers L., Takimoto C., Curt G., Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997, 51:193-200.
55. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
56. Eisenmann K.M., VanBrocklin M.W., Staffend N.A., Kitchen S.M., Koo H.M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003, 63:8330-8337.